Loading... Please wait... Loading... Please wait...
ESTIMATED
04/30/2024
04/30/2024
(AS OF MARCH 31)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.02 | -$0.02 | -$0.02 |
| Q2 2024 | 7 | $0.11 | $0.29 | $0.21 |
| Q3 2024 | 2 | $0.15 | $0.15 | $0.15 |
| Q4 2024 | 2 | $0.10 | $0.10 | $0.10 |
| Q1 2025 | 3 | $0.23 | $0.23 | $0.23 |
| Q2 2025 | 3 | $0.23 | $0.23 | $0.23 |
| Q3 2025 | 3 | $0.25 | $0.25 | $0.25 |
| Q4 2025 | 6 | $0.27 | $0.27 | $0.27 |
TransMedics Group, Inc. last posted its earnings results on Tuesday, April 30th, 2024. The company reported $0.35 earnings per share for the quarter, topping analysts' consensus estimates of $0.03256 by $0.31744. The company had revenue of 96.85 M for the quarter and had revenue of 241.62 M for the year. TransMedics Group, Inc. has generated $-1 earnings per share over the last year ($-0.77 diluted earnings per share) and currently has a price-to-earnings ratio of -480.49. TransMedics Group, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 1st, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/02/2024 | Q1 2024 | $0.37 | $83.78 M | $96.85 M | 02/27/2024 | Q4 2023 | $0.12 | $68.49 M | $81.17 M | 11/08/2023 | Q3 2023 | -$0.78 | $66.43 M | 08/04/2023 | Q2 2023 | -$0.03 | $52.47 M | 05/04/2023 | Q1 2023 | -$0.08 | $37.93 M | $41.55 M | 02/27/2023 | Q4 2022 | -$0.21 | $24.45 M | $31.38 M | 11/04/2022 | Q3 2022 | -$0.25 | $25.68 M | 08/03/2022 | Q2 2022 | -$0.41 | $20.52 M | 05/05/2022 | Q1 2022 | -$0.38 | $15.88 M | 03/01/2022 | Q4 2021 | -$0.46 | $7.51 M | $9.67 M | 11/09/2021 | Q3 2021 | -$0.32 | -$0.47 | -0.15 | $6.34 M | $5.37 M | 08/06/2021 | Q2 2021 | -$0.39 | $7.42 M | $8.17 M | 05/07/2021 | Q1 2021 | -$0.29 | $7.05 M | 03/11/2021 | Q4 2020 | -$0.23 | $6.06 M | $7.63 M | 11/06/2020 | Q3 2020 | -$0.19 | $5.55 M | $7.09 M | 08/07/2020 | Q2 2020 | -$0.36 | $2.75 M | $3.39 M | 05/06/2020 | Q1 2020 | -$0.39 | -$0.42 | -0.03 | $7.53 M | 03/17/2020 | Q4 2019 | -$0.43 | $6.06 M | 11/08/2019 | Q3 2019 | -$0.39 | $7.21 M | 08/08/2019 | Q2 2019 | -$0.70 | $5.67 M |
|---|
A. TransMedics Group, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 1st, 2024 based off last year's report dates.
A. In the previous quarter, TransMedics Group, Inc. (NASDAQ:TMDX) reported $0.35 earnings per share (EPS) to beat the analysts' consensus estimate of $0.03256 by $0.31744.
A. The conference call for TransMedics Group, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for TransMedics Group, Inc.'s latest earnings report can be read online.
A. TransMedics Group, Inc. (NASDAQ:TMDX) has a recorded annual revenue of $241.62 M.
A. TransMedics Group, Inc. (NASDAQ:TMDX) has a recorded net income of $241.62 M. TransMedics Group, Inc. has generated $-0.77 earnings per share over the last four quarters.
A. TransMedics Group, Inc. (NASDAQ:TMDX) has a price-to-earnings ratio of -480.49 and price/earnings-to-growth ratio is -12.85.
